OBJECTIVES
Lenacapavir, a first-in-class, long-acting capsid inhibitor (CAI), has been approved for HIV-1 treatment and prevention. However, naturally occurring resistance to the HIV-1 CAI at the quasi-species level is rarely reported.
METHODS
Using next-generation sequencing (NGS), we obtained 495 HIV-1 near-full-le...
Pei-Jiang Pan, Cai-Chang Mo, Rong-Feng Chen et al.· Journal of Antimicrobial Che...· 0 citations
Based on the combined phylogenetic, chemotaxonomic, and phenotypic evidence, the two strains could be classified as a novel species within the genus Leucobacter, for which the name Leucobacter faecis sp.
Yu-Yuan Huang, Jing Yang, Qinglian Qin et al.· Current Microbiology· 0 citations
Analysis of HIV-1 samples collected from two male patients in Shenzhen suggested that the recombination between CRF01_AE and CRF07_BC continued to occur in Shenzhen, potentially contributing to the increasing genetic complexity of the local HIV-1 epidemic.
Dandan Lin, Bo Zhu, Shengya Liu et al.· AIDS Research and Human Retr...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.